Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Volume: 11, Issue: 10
Published: Oct 4, 2021
Abstract
To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was...
Paper Details
Title
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
Published Date
Oct 4, 2021
Volume
11
Issue
10
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.